Irvine, CA, United States of America

Felix Mesak



 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Felix Mesak: Innovator in Medical Imaging

Introduction

Felix Mesak is a notable inventor based in Irvine, CA (US). He has made significant contributions to the field of medical imaging, particularly in the development of compositions targeting the bradykinin receptor B1. His work has implications for cancer diagnosis and treatment.

Latest Patents

Felix Mesak holds 1 patent for his invention titled "Compositions targeting bradykinin receptor B1 for medical imaging of cancer and other disorders." This patent involves bradykinin B1 receptor (B1R) targeting peptides and compounds that are radiolabelled with radioisotopes suitable for imaging and/or radiotherapy. The radiolabelled peptides and compounds are designed to image tissues that express or overexpress B1R, and they have potential utility in treating diseases or conditions associated with B1R, including cancer.

Career Highlights

Throughout his career, Felix has worked with prominent organizations such as the British Columbia Cancer Agency and the Provincial Health Services Authority. His experience in these institutions has allowed him to contribute to advancements in cancer research and medical imaging technologies.

Collaborations

Felix has collaborated with esteemed colleagues, including Kuo-shyan Lin and François Bénard. These partnerships have further enriched his research and innovation efforts in the medical field.

Conclusion

Felix Mesak's innovative work in medical imaging, particularly through his patent on bradykinin receptor B1 targeting, showcases his commitment to advancing cancer diagnosis and treatment. His contributions are significant in the ongoing fight against cancer and other related disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…